Roblee P Allen MD

Pulmonology•Sacramento, CA

Critical Care Medicine, Pleural Disease

Professor, Internal Medicine, UC, Davis School of Medicine

Join to View Full Profile

2315 Stockton BlvdMain HospitalSacramento, CA 95817
Phone+1 916-734-3564
Fax+1 916-734-7924

Education & Training

University of California Davis HealthFellowship, Pulmonary Disease and Critical Care Medicine, 1982 - 1984
Tulane UniversityResidency, Internal Medicine, 1978 - 1980
Medical University of South CarolinaClass of 1978

Certifications & Licensure

CA State Medical License 1982 - 2024
LA State Medical License 1978 - 1981
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Super Doctor SuperDoctors.com

Clinical Trials

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPLETED
PHASE4
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
COMPLETED
PHASE3
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Completed
Phase 3
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Start of enrollment: 2013 Sep 11
Completed
Phase 3
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Start of enrollment: 2014 May 31
Completed
Phase 2
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis Start of enrollment: 2016 Feb 01
Withdrawn
Phase 2
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER Start of enrollment: 2017 Apr 18
Terminated
Phase 3
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 Start of enrollment: 2019 Apr 10
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
An expert panel delphi consensus statement on patient selection and management for transitioning between oral and inhaled treprostinil.
Franck Rahaghi, Roblee P Allen, Vijay Balasubramanian, Murali M. Chakinala, Jean M. Elwing
Pulmonary Pharmacology & Therapeutics. 2021-02-01
274 citations
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Aaron B. Waxman, Ricardo Restrepo-Jaramillo, Thenappan Thenappan, Ashwin Ravichandran, Peter A. Engel
The New England Journal of Medicine. 2021-01-28
1 citations
Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics:
R. James White, Keyur Parikh, Roblee P Allen, Jeremy Feldman, Carlos Jerjez-Sanchez
Pulmonary Circulation. 2020-12-08